ZYNERBA PHARMACEUTICALS INC (ZYNE) Stock Fundamental Analysis

NASDAQ:ZYNE • US98986X1090

1.3 USD
+0.03 (+2.36%)
At close: Oct 10, 2023
1.3015 USD
+0 (+0.12%)
After Hours: 10/10/2023, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall ZYNE gets a fundamental rating of 2 out of 10. We evaluated ZYNE against 191 industry peers in the Pharmaceuticals industry. While ZYNE seems to be doing ok healthwise, there are quite some concerns on its profitability. ZYNE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ZYNE has reported negative net income.
  • ZYNE had a negative operating cash flow in the past year.
ZYNE Yearly Net Income VS EBIT VS OCF VS FCFZYNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

  • The Return On Assets of ZYNE (-92.85%) is worse than 78.47% of its industry peers.
  • ZYNE's Return On Equity of -129.50% is on the low side compared to the rest of the industry. ZYNE is outperformed by 67.94% of its industry peers.
Industry RankSector Rank
ROA -92.85%
ROE -129.5%
ROIC N/A
ROA(3y)-59.46%
ROA(5y)-55.04%
ROE(3y)-71.26%
ROE(5y)-65.33%
ROIC(3y)N/A
ROIC(5y)N/A
ZYNE Yearly ROA, ROE, ROICZYNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ZYNE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYNE Yearly Profit, Operating, Gross MarginsZYNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -50K -100K -150K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ZYNE has more shares outstanding
  • ZYNE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZYNE Yearly Shares OutstandingZYNE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
ZYNE Yearly Total Debt VS Total AssetsZYNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

  • ZYNE has an Altman-Z score of -8.88. This is a bad value and indicates that ZYNE is not financially healthy and even has some risk of bankruptcy.
  • ZYNE's Altman-Z score of -8.88 is on the low side compared to the rest of the industry. ZYNE is outperformed by 74.64% of its industry peers.
  • ZYNE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.88
ROIC/WACCN/A
WACCN/A
ZYNE Yearly LT Debt VS Equity VS FCFZYNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • ZYNE has a Current Ratio of 3.43. This indicates that ZYNE is financially healthy and has no problem in meeting its short term obligations.
  • ZYNE has a Current ratio (3.43) which is in line with its industry peers.
  • ZYNE has a Quick Ratio of 3.43. This indicates that ZYNE is financially healthy and has no problem in meeting its short term obligations.
  • ZYNE has a Quick ratio of 3.43. This is comparable to the rest of the industry: ZYNE outperforms 52.63% of its industry peers.
Industry RankSector Rank
Current Ratio 3.43
Quick Ratio 3.43
ZYNE Yearly Current Assets VS Current LiabilitesZYNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 13.98% over the past year.
EPS 1Y (TTM)13.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 31.48% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.82%
EPS Next 2Y10.85%
EPS Next 3Y15.71%
EPS Next 5Y31.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYNE Yearly Revenue VS EstimatesZYNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
ZYNE Yearly EPS VS EstimatesZYNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ZYNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZYNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYNE Price Earnings VS Forward Price EarningsZYNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYNE Per share dataZYNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

  • ZYNE's earnings are expected to grow with 15.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.85%
EPS Next 3Y15.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ZYNE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ZYNERBA PHARMACEUTICALS INC

NASDAQ:ZYNE (10/10/2023, 8:00:03 PM)

After market: 1.3015 +0 (+0.12%)

1.3

+0.03 (+2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14
Earnings (Next)11-13
Inst Owners0.03%
Inst Owner Change0%
Ins Owners2.98%
Ins Owner Change0%
Market Cap70.12M
Revenue(TTM)N/A
Net Income(TTM)-37.58M
Analysts48.89
Price Target1.28 (-1.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.52%
Min EPS beat(2)-8.36%
Max EPS beat(2)-4.68%
EPS beat(4)2
Avg EPS beat(4)1.11%
Min EPS beat(4)-8.36%
Max EPS beat(4)12.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-78.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)145%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.91%
Revenue NQ rev (1m)99900%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.42
P/tB 2.42
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0
BVpS0.54
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -92.85%
ROE -129.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.46%
ROA(5y)-55.04%
ROE(3y)-71.26%
ROE(5y)-65.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.34%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.43
Quick Ratio 3.43
Altman-Z -8.88
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)101.27%
Cap/Depr(5y)138.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y-2.82%
EPS Next 2Y10.85%
EPS Next 3Y15.71%
EPS Next 5Y31.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.8%
EBIT Next 3Y1.94%
EBIT Next 5Y31.42%
FCF growth 1Y9.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.18%
OCF growth 3YN/A
OCF growth 5YN/A

ZYNERBA PHARMACEUTICALS INC / ZYNE FAQ

What is the fundamental rating for ZYNE stock?

ChartMill assigns a fundamental rating of 2 / 10 to ZYNE.


What is the valuation status of ZYNERBA PHARMACEUTICALS INC (ZYNE) stock?

ChartMill assigns a valuation rating of 0 / 10 to ZYNERBA PHARMACEUTICALS INC (ZYNE). This can be considered as Overvalued.


Can you provide the profitability details for ZYNERBA PHARMACEUTICALS INC?

ZYNERBA PHARMACEUTICALS INC (ZYNE) has a profitability rating of 0 / 10.


What is the financial health of ZYNERBA PHARMACEUTICALS INC (ZYNE) stock?

The financial health rating of ZYNERBA PHARMACEUTICALS INC (ZYNE) is 6 / 10.


What is the expected EPS growth for ZYNERBA PHARMACEUTICALS INC (ZYNE) stock?

The Earnings per Share (EPS) of ZYNERBA PHARMACEUTICALS INC (ZYNE) is expected to decline by -2.82% in the next year.